Kalexo Bio
PrivateLast Round
Corporate Funding
Sep 17, 2025
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Kalexo Bio is a drug discovery company that develops siRNA-based therapeutics for the treatment of cardiovascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kalexo Bio Comparables
Compare Kalexo Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sirius Therapeutics, Inc. | 86% | |
| Rona Therapeutics | 84% | |
| Suzhou Siran Biotechnology Co., Ltd. | 77% | |
Kalexo Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Sep 17, 2025 |
Kalexo Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aditum Bio | Corporate Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2025
Led by Aditum Bio with participation from Mabwell.
Kalexo Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kalexo Bio's valuation, stock price, and market status.